Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05451940 · ClinicalTrials.gov registry record · Phase 1

Hydroxyurea and EPO in Sickle Cell Disease

A Phase 1 study of Sickle Cell Disease and Anemia, Sickle Cell, sponsored by Julia Xu.

Completed
Registry status
Phase 1
Development phase
17
Enrollment target
2
Study locations

NCT05451940: Completed Phase 1 study of Sickle Cell Disease and Anemia, Sickle Cell, sponsored by Julia Xu.

NCT05451940 is a Phase 1 study of Sickle Cell Disease and Anemia, Sickle Cell that has completed, run by Julia Xu. The registered enrollment target is 17 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05451940, a Phase 1 study of Sickle Cell Disease and Anemia, Sickle Cell, has completed, sponsored by Julia Xu.

COMPLETED
Registry status
Phase 1
Development phase
17 participants
Enrollment target
2
Study locations

Study Summary

The proposed study is a Phase 1/2 multi-center study evaluating the safety and efficacy of erythropoietin (EPO) in combination with hydroxyurea in the treatment of chronic anemia in patients with sickle cell disease (SCD).

Conditions Studied

Sickle Cell Disease Anemia, Sickle Cell

Interventions

  • DRUG Hydroxyurea
  • DRUG Epoetin Alfa-BioSimilar

Study Locations (2)

Pennsylvania

  • UPMC - Pittsburgh

Other

  • Lagos University Teaching Hospital - Lagos

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2023-05-25
Est. Completion 2025-02-27
Phase Phase 1

Sponsor

Julia Xu

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05451940

The ClinicalTrials.gov registry entry for NCT05451940 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (94% lower). The listed sponsor is Julia Xu, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Hydroxyurea is the first listed.

NCT05451940 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Other.

Frequently Asked Questions

What is clinical trial NCT05451940 about?

NCT05451940 is a clinical study titled "Hydroxyurea and EPO in Sickle Cell Disease". The proposed study is a Phase 1/2 multi-center study evaluating the safety and efficacy of erythropoietin (EPO) in combination with hydroxyurea in the treatment of chronic anemia in patients with sickle cell disease (SCD).

What is the current status of trial NCT05451940?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2023-05-25. Estimated completion is 2025-02-27.

What conditions does trial NCT05451940 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Anemia, Sickle Cell.

What interventions are being tested in trial NCT05451940?

The interventions under investigation include: Hydroxyurea (DRUG), Epoetin Alfa-BioSimilar (DRUG).

Who is sponsoring clinical trial NCT05451940?

This trial is sponsored by Julia Xu, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05451940 being conducted?

This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Anemia, Sickle Cell

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.